Cargando…
An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
T-cell malignancies are associated with frequent relapse and high morbidity, which is partly due to the lack of effective or targeted treatment options. To broaden the use of CAR-T cells in pan T-cell malignancies, we developed an allogeneic “universal” CD2-targeting CAR-T cell (UCART2), in which th...
Autores principales: | Xiang, Jingyu, Devenport, Jessica M., Carter, Alun J., Staser, Karl W., Kim, Miriam Y., O’ Neal, Julie, Ritchey, Julie K., Rettig, Michael P., Gao, Feng, Rettig, Garrett, Turk, Rolf, Lee, Byung Ha, Cooper, Matthew L., DiPersio, John F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681896/ https://www.ncbi.nlm.nih.gov/pubmed/37798328 http://dx.doi.org/10.1038/s41375-023-02039-z |
Ejemplares similares
-
An ‘off-the-shelf’ fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
por: Cooper, Matthew L., et al.
Publicado: (2018) -
A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity
por: Kim, Miriam Y., et al.
Publicado: (2022) -
Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc
por: O’Neal, Julie, et al.
Publicado: (2023) -
CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy
por: Kim, Miriam Y., et al.
Publicado: (2021) -
CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells
por: O’Neal, Julie, et al.
Publicado: (2022)